Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

(2012) Yuichiro Eguchi et al.   JOURNAL OF GASTROENTEROLOGY

Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography

(2012) Victor Lédinghen et al.   LIVER INTERNATIONAL

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography

(2012) Robert P. Myers et al.   LIVER INTERNATIONAL

Safety and Feasibility of Diet-Treated Donors With Steatotic Livers at the Initial Consultation for Living-Donor Liver Transplantation

(2012) Akihiko Oshita et al.   TRANSPLANTATION

Extremely Marginal Liver Grafts From Deceased Donors Have Outcome Similar to Ideal Grafts

(2012) N. Goldaracena et al.   TRANSPLANTATION PROCEEDINGS

Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD

(2011) Mireen Friedrich-Rust et al.   EUROPEAN JOURNAL OF RADIOLOGY

Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?

(2011) Indra Neil Guha et al.   HEPATOLOGY

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

(2011) Takeshi Okanoue et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

(2011) M. Sasso et al.   JOURNAL OF VIRAL HEPATITIS

The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®

(2011) M. Sasso et al.   Clinics and Research in Hepatology and Gastroenterology

Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis

(2010) Dina G. Tiniakos et al.   Annual Review of Pathology-Mechanisms of Disease

Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy

(2010) Shosuke Kitamura et al.   ANTIVIRAL THERAPY

Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes

(2010) Magali Sasso et al.   ULTRASOUND IN MEDICINE AND BIOLOGY

Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy

(2009) S. Nagai et al.   BRITISH JOURNAL OF SURGERY

Non-invasive diagnosis of steatosis and fibrosis

(2009) L. Castera   DIABETES & METABOLISM

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

(2009) Takeshi Okanoue et al.   JOURNAL OF GASTROENTEROLOGY

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

(2009) Nina F. Schwenzer et al.   JOURNAL OF HEPATOLOGY

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

(2009) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Liver Transplantation: The Current Situation

(2009) Rene Adam et al.   SEMINARS IN LIVER DISEASE

Noninvasive Assessment of Hepatic Steatosis

(2008) Sameer M. Mazhar et al.   Clinical Gastroenterology and Hepatology